| Literature DB >> 28211573 |
Slavica Vuckovic1,2,3, Kate Vandyke4,5, David A Rickards6, Padraig McCauley Winter6, Simon H J Brown7, Todd W Mitchell7, Jun Liu8, Jun Lu8, Philip W Askenase9, Elizabeth Yuriev10, Ben Capuano10, Paul A Ramsland11,12,13,14, Geoffrey R Hill1,15, Andrew C W Zannettino4,5, Andrew T Hutchinson6,9,12.
Abstract
We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine - a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers.Entities:
Keywords: GW4869; multiple myeloma; phosphatidylserine; small molecule
Mesh:
Substances:
Year: 2017 PMID: 28211573 DOI: 10.1111/bjh.14561
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 8.615